Tekla Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Tekla Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-88,102	Closed	-$384K	–	197
2021 Q2	$384K	Hold	88,102	–	–	0.01%	184
2021 Q1	$400K	Hold	88,102	–	–	0.01%	189
2020 Q4	$506K	Hold	88,102	–	–	0.02%	191
2020 Q3	$638K	Hold	88,102	–	–	0.02%	190
2020 Q2	$307K	Hold	88,102	–	–	0.01%	216
2020 Q1	$130K	Hold	88,102	–	–	0.01%	208
2019 Q4	$173K	Hold	88,102	–	–	0.01%	206
2019 Q3	$451K	Hold	88,102	–	–	0.02%	174
2019 Q2	$631K	Buy	+88,102	New	+$998K	0.03%	178
2018 Q4	–	Sell	-169,962	Closed	-$1.88M	–	214
2018 Q3	$1.88M	Hold	169,962	–	–	0.07%	160
2018 Q2	$2.28M	Hold	169,962	–	–	0.09%	132
2018 Q1	$2.21M	Sell	169,962 -40,000	-19%	-$497K	0.09%	131
2017 Q4	$1.93M	Hold	209,962	–	–	0.07%	129
2017 Q3	$1.69M	Buy	+209,962	New	+$1.42M	0.06%	127

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Tekla Capital Management's CBAY Position: Q3 2021 in Review

Tekla Capital Management sold out of Cymabay Therapeutics (CBAY) in Q3 2021, closing a stake of 88,102 shares — an estimated $384K sold.

Tekla Capital Management first reported a position in CBAY in Q3 2017 and held it in 14 quarters. The position peaked at $2.28M in Q2 2018. 113 funds tracked by Wall St. Rank hold CBAY as of Q3 2021.

Tekla Capital Management reported no remaining Cymabay Therapeutics position as of Q3 2021 after selling out during the quarter.
Tekla Capital Management sold 88,102 Cymabay Therapeutics shares in Q3 2021, an estimated $384K.
Tekla Capital Management first reported a position in Cymabay Therapeutics in Q3 2017 and held it in 14 quarters.
Tekla Capital Management's Cymabay Therapeutics position peaked at $2.28M in Q2 2018.
113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2021.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.